Search
for
Sort by
Research 271–300 of 1000+
- Estimating the risk of irreversible post-SSRI sexual dysfunction (PSSD) due to serotonergic antidepressants
- Volume imaging to interrogate cancer cell-tumor microenvironment interactions in space and time
- Neurotoxins Acting at Synaptic Sites: A Brief Review on Mechanisms and Clinical Applications
- Autologous Platelet and Extracellular Vesicle-Rich Plasma as Therapeutic Fluid: A Review
- COVID-19 and hypopituitarism
- Anxiety in the Medically Ill: A Systematic Review of the Literature
- Enzyme Inhibitors from Gorgonians and Soft Corals
- Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database
- Adult Male Hypogonadism: A Laboratory Medicine Perspective on Its Diagnosis and Management
- The Multiple Consequences of Obesity
- RAGE and Its Ligands in Melanoma
- Molecular Morbidity Score–Can MicroRNAs Assess the Burden of Disease?
- Role of testosterone in SARS-CoV-2 infection: A key pathogenic factor and a biomarker for severe pneumonia
- The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia
- Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor
- DIHYDROTESTOSTERONE AND THE PROSTATE: THE SCIENTIFIC RATIONALE FOR 5α-REDUCTASE INHIBITORS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
- Three-Month Treatment With a Long-Acting Gonadotropin-Releasing Hormone Agonist of Patients With Benign Prostatic Hyperplasia: Effects on Tissue Androgen Concentration, 5<i>α</i>-Reductase Activity and Androgen Receptor Content*
- What do we know about phytotherapy of benign prostatic hyperplasia?
- Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis
- Association of Benign Prostatic Hyperplasia with Male Pattern Baldness
- Prevalence of metabolic syndrome and its components among men with and without clinical benign prostatic hyperplasia: a large, cross-sectional, UK epidemiological study
- Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink
- Androgenetic alopecia as an early marker of benign prostatic hyperplasia
- Current evidence for the involvement of sex steroid receptors and sex hormones in benign prostatic hyperplasia
- Dutasteride for the treatment of benign prostatic hyperplasia
- Benign Prostatic Hyperplasia: A Disorder of Androgen Metabolism in the Male
- Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms?: a systematic review
- Comparative Study of Therapeutic Effect of Dibenyline, Finasteride, and Combination Drugs for Symptomatic Benign Prostatic Hyperplasia
- Neuropsychological Assessment in Elderly Men with Benign Prostatic Hyperplasia Treated with Dutasteride
- Finasteride and Erectile Dysfunction in Patients with Benign Prostatic Hyperplasia or Male Androgenetic Alopecia